Clinical-stage company offers a disruptive outpatient treatment solution addressing the top global healthcare cost driver: recurring admissions of congested Chronic Heart Failure patients. Our implanted, connected device removes excess fluid and salt and clears them to the patient’s bladder, providing continuous decongestion: personalized precise treatment with no patient involvement, out-of-hospital. Clinical trials are underway with strong results from an initial series of patients. Our target US market is 1.2M+ annual hospitalizations which generate $30B+ of hospital losses and payor costs, most of which are avoidable with our technology. ROW market is larger.